Clinical Trials Browser

Lymphoma, Follicular, Myelodysplastic Syndromes, Myeloproliferative Disorders, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone, Hematologic Neoplasms, Lymphoma, Mantle-Cell

NCT02096042 2023-10-10

Phase I/II - Brentuximab/5-Azacytidine in Acute Myeloid Leukemia (AML)

Phase 1/2 Terminated

1 enrolled 3 charts

Other hematologic neoplasm

Leukemia, Recurrence, Leukemia, Myeloid, Acute

NCT05797948 2023-04-04

GZL Sequential CD19/CD22 CAR-T in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Phase NA Unknown

20 enrolled

Lymphoid

Recurrence, Lymphoma, B-Cell

NCT04809181 2023-02-21

Azacitidine in Combination With Venetoclax Treatment for MRD Positive Post Allo-HSCT AML/MDS Patients

Phase 2 Unknown

95 enrolled

Other hematologic neoplasm

Recurrence, Hematologic Neoplasms

NCT04913922 2022-11-08

AARON

Phase 2 Unknown

30 enrolled

Other hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute

NCT03825367 2022-10-12

Nivolumab in Combination With 5-azacytidine in Childhood Relapsed/Refractory AML

Phase 1/2 Unknown

13 enrolled

Other hematologic neoplasm

Leukemia, Recurrence, Leukemia, Myeloid, Acute

NCT04722952 2021-12-03

PD-1 Inhibitor Combined With Azacytidine and Homoharringtonine，Cytarabine, G-CSF for Refractory or Relapsed AML

Phase 3 Unknown

30 enrolled

Other hematologic neoplasm

Leukemia, Recurrence, Leukemia, Myeloid, Acute

NCT02319369 2021-10-11

Safety, Tolerability and Pharmacokinetics of Milademetan Alone and With 5-Azacitidine (AZA) in Acute Myelogenous Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)

Phase 1 Terminated

74 enrolled 30 charts

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Recurrence, Leukemia, Myeloid, Acute

NCT01861002 2021-06-09

A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML

Phase 1 Completed

15 enrolled 10 charts

LymphoidOther hematologic neoplasm

Leukemia, Leukemia, Myeloid, Recurrence, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02017457 2019-12-10

Azacytidine and Lymphocytes in Relapse of AML or MDS After Allogeneic Stem Cell Transplantation.

Phase 2 Completed

50 enrolled

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Recurrence, Leukemia, Myeloid, Acute

NCT02954653 2019-11-21

A Study Of PF-06747143, As Single Agent Or In Combination With Standard Chemotherapy In Adult Patients With Acute Myeloid Leukemia

Phase 1 Terminated

8 enrolled 13 charts

Other hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute

NCT01478685 2019-11-12

A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors

Phase 1 Completed

169 enrolled

GastrointestinalGenitourinaryGynecologicThoracic

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Fallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms, Recurrence, Tumor Virus Infections, Carcinoma, Pancreatic Ductal

NCT02269943 2018-12-12

Safety and Efficacy of CC-486 in Previously Treated Patients With Locally Advanced or Metastatic Nasopharyngeal Carcinoma

Phase 2 Completed

36 enrolled 24 charts

Head & Neck

Nasopharyngeal Carcinoma, Head and Neck Neoplasms, Nasopharyngeal Neoplasms, Neoplasm Metastasis, Neoplasms, Recurrence, Epstein-Barr Virus Infections

NCT02204020 2018-03-30

UPCI 13-165

Phase 2 Withdrawn

MyeloidOther hematologic neoplasm

Graft vs Host Disease, Myelodysplastic Syndromes, Recurrence, Leukemia, Myeloid, Acute

NCT01121757 2016-09-12

Epigenetic Modulation in Relapsed/Refractory Follicular Lymphoma and Marginal Zone Lymphoma

Phase 2 Terminated

11 enrolled 12 charts

Lymphoid

Lymphoma, Lymphoma, Follicular, Recurrence, Lymphoma, B-Cell, Marginal Zone

NCT00351975 2014-12-23

Belinostat and Azacitidine in Treating Patients With Advanced Hematologic Cancers or Other Diseases

Phase 1 Completed

56 enrolled

LymphoidMyeloidOther hematologic neoplasm

Blast Crisis, Myeloproliferative Disorders, Recurrence, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Leukemia, Promyelocytic, Acute, Leukemia, Myelomonocytic, Chronic, Leukemia, Myelomonocytic, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT00412919 2013-12-16

Study of Azacitidine to Treat Relapsed or Refractory Multiple Myeloma

Phase 2 Terminated

7 enrolled

Plasma cell

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

Clinical Trials

A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)

Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML

Venetoclax Basket Trial for High Risk Hematologic Malignancies

Dose-Escalation Study of Oral Administration of LP-108 as Monotherapy and in Combination With Azacitidine in Patients With Relapsed or Refractory MDS, CMML, or AML

Cladribine Venetoclax in Monocytic AML

TUSCANY

IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia

AMG 176 First in Human Trial in Participants With Relapsed or Refractory Multiple Myeloma and Participants With Relapsed or Refractory Acute Myeloid Leukemia

A Phase 1 Study With LYT-200 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML), or With Relapsed/Refractory, High-risk Myelodysplastic Syndrome (MDS)

Demethylating Agents Combined With Venetoclax for High-risk T-cell Lymphoblastic Lymphoma/Leukemia Post-Transplant Relapse Prevention

DEXAML-03

Azacitidine Combined with Donor Lymphocyte Infusion for Acute Myeloid Leukemia Post-transplant Relapse Prevention.

Safety and Efficacy of Avapritinib in Relapsed or Refractory Pediatric CBF-AML With KIT Mutation

Phase IIa Study to Assess Safety and Efficacy in the Relapsed/Refractory Acute Myeloid Leukemia

A Study of Sabatolimab and Magrolimab-based Treatment in AML or Higher Risk MDS Participants

PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies

Phase I/II - Brentuximab/5-Azacytidine in Acute Myeloid Leukemia (AML)

GZL Sequential CD19/CD22 CAR-T in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Azacitidine in Combination With Venetoclax Treatment for MRD Positive Post Allo-HSCT AML/MDS Patients

AARON

Nivolumab in Combination With 5-azacytidine in Childhood Relapsed/Refractory AML

PD-1 Inhibitor Combined With Azacytidine and Homoharringtonine，Cytarabine, G-CSF for Refractory or Relapsed AML

Safety, Tolerability and Pharmacokinetics of Milademetan Alone and With 5-Azacitidine (AZA) in Acute Myelogenous Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)

A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML

Azacytidine and Lymphocytes in Relapse of AML or MDS After Allogeneic Stem Cell Transplantation.

A Study Of PF-06747143, As Single Agent Or In Combination With Standard Chemotherapy In Adult Patients With Acute Myeloid Leukemia

A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors

Safety and Efficacy of CC-486 in Previously Treated Patients With Locally Advanced or Metastatic Nasopharyngeal Carcinoma

UPCI 13-165

Epigenetic Modulation in Relapsed/Refractory Follicular Lymphoma and Marginal Zone Lymphoma

Belinostat and Azacitidine in Treating Patients With Advanced Hematologic Cancers or Other Diseases

Study of Azacitidine to Treat Relapsed or Refractory Multiple Myeloma